Aptorum Group Limited (NASDAQ: APM)
$4.14
-0.3900 ( -8.61% ) 51.7K
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
Market Data
Open
$4.14
Previous close
$4.53
Volume
51.7K
Market cap
$23.58M
Day range
$4.14 - $4.60
52 week range
$1.35 - $17.49
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 2 | May 31, 2024 |
6-k | Quarterly Reports | 3 | Apr 30, 2024 |
20-f | Annual reports | 126 | Apr 30, 2024 |
6-k | Quarterly Reports | 6 | Mar 06, 2024 |
6-k | Quarterly Reports | 91 | Dec 22, 2023 |
6-k | Quarterly Reports | 3 | Dec 21, 2023 |
6-k | Quarterly Reports | 1 | Nov 30, 2023 |
6-k/a | Quarterly Reports | 1 | Nov 21, 2023 |
6-k | Quarterly Reports | 7 | Nov 16, 2023 |
6-k | Quarterly Reports | 2 | Sep 11, 2023 |